<h3>Introduction</h3> Dupilumab is a first-in-class immunobiologic that has demonstrated significant clinical results in treatment of atopic diseases like atopic dermatitis (AD) and asthma. However, adverse ocular surface symptoms arise with treatment at rates of 9-22%. <h3>Methods</h3> Case series of two AKC (atopic keratoconjunctivitis) patients from 2018-2022 were evaluated using Ocular Surface Disease Index (OSDI), Total Ocular Symptom Score (TOSS), SCORing AD (SCORAD), and Asthma Control Test (ACT) assessments. <h3>Results</h3> A 16-year-old female was referred for lifetime AD, asthma, and ocular symptoms consistent with AKC. Mycophenolate and cyclosporine were discontinued due to adverse effects. Benrazilumab 30 mg q4wk resulted in SCORAD decrease (53.7 to 36.2), but the patient still had eczematous lesions, periocular dermatitis, and tearing. Benrazilumab was discontinued and dupilumab 300 mg q2wk was initiated, resulting in improvement within two weeks; she denied conjunctival injections, tearing, OSDI (30 to 6.8), TOSS (25 to 12.5), and SCORAD (36.2 to 23.25). A 20-year-old male with a history of AD, asthma, allergic rhinitis, eosinophilic esophagitis, vernal conjunctivitis, and persistent central corneal ulcers OD presented with pruritus and photophobia. Cyclosporine, cromolyn sodium and prednisone acetate had limited success. Initiation of dupilumab 300 mg q2wk led to near resolution of ocular surface symptoms within three months, OSDI (66.6 to 8.3), TOSS (100 to 6.25), along with resolution of upper AD lesions by 90% and ACT of 24. <h3>Conclusion</h3> Dupilumab, despite its reported adverse ocular surface effects, remediated AKC ocular surface symptoms in addition to improving AD and asthma.